Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Pro
Company advances its internally developed drug discovery program targeting acute graft-versus-host d
Company advances its internally developed drug discovery program targeting acute graft-versus-host d